Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
REGULATORY
Japan Agrees to Buy Extra 10 Million Doses of Pfizer COVID Vaccine
The Japanese government said on September 27 that it has agreed with Pfizer to purchase an additional 10 million doses of the company’s monovalent COVID-19 vaccine adapted to the Omicron XBB.1.5 strain. The additional doses of the mRNA jab, Comirnaty,…
To read the full story
Related Article
- Japan to Buy 10 Million More Doses of Pfizer/Moderna COVID Jabs
October 19, 2023
- Japan Panel OKs Use of Pfizer’s XBB.1.5 Jab for Fall Vaccination Campaign
September 11, 2023
- Japan Approves Pfizer’s Omicron XBB.1.5 Vaccine, Moderna’s Still under Review
September 4, 2023
- Japan Panel OKs Rollout of XBB.1.5-Based COVID Vaccines on Sept. 20
August 10, 2023
- Moderna Japan’s XBB-Based COVID Jab Actually Filed for Age 6 and Up
August 3, 2023
- Japan to Buy 20 Million Doses of Pfizer COVID Jab, 5 Million from Moderna
July 28, 2023
- Japan Likely to Slash Moderna Vaccine Purchase, Pfizer Single-Sourcing Plan Nixed
July 28, 2023
- Pfizer, Moderna File Updated COVID-19 Vaccines in Japan
July 7, 2023
- Japan Mulls Narrowing Down COVID-19 Jabs to Pfizer, but Some Lawmakers Are Skeptical
June 29, 2023
REGULATORY
- MOF Presses for Full FY2027 Drug Price Revision Without Price Gap Thresholds
November 4, 2026
- Japan Panel to Review Kyowa Kirin’s Libmeldy for Approval on Nov. 9
November 4, 2026
- PMDA Sets Out AI Principles for Regulatory Activities, Stresses Human Oversight
November 4, 2026
- Public-Private Pharma Talks Expand to Domestic R&D, Manufacturing Investment
November 2, 2026
- Japan’s Healthcare Spending Hits Record 48.8 Trillion Yen in FY2024
November 2, 2026
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…